The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy

Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults

(2009) Josep Mallolas et al.   AIDS

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

(2009) Jean-François Delfraissy et al.   AIDS

Relationship between Adherence Level, Type of the Antiretroviral Regimen, and Plasma HIV Type 1 RNA Viral Load: A Prospective Cohort Study

(2008) M. Martin et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Forgiveness of non-adherence to HIV-1 antiretroviral therapy

(2008) J. Shuter   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination Therapy

(2008) D. William Cameron et al.   JOURNAL OF INFECTIOUS DISEASES

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA